Corgenix files diagnostics with FDA:
This article was originally published in Clinica
Executive Summary
Corgenix Medical has submitted for US marketing approval two new tests for the diagnosis and risk assessment of certain cardiovascular disorders that are characterised by blood clot formation. The IgG anti-Prothrombin and IgM anti-Prothrombin antibody test kits will be added to the Denver, Colorado company's range of ELISA-based diagnostic assays for antiphospholipid antibodies, which are sold to clinical laboratories.